Overview
To follow up the efficacy and safety of Candida antigen, bivalent HPV vaccine in treatment of common warts either mono or combined intralesional therapy
Description
- Group A: 54 patients will be treated with Candida antigen. All patients will be
directly injected with Candida antigen into the largest wart using an insulin
syringe. Injections will be done at 2-week intervals until complete clearance will
be achieved or for a maximum of five treatment sessions.
- Group B: 54 patients will be treated with bivalent HPV vaccine solution intralesional into the largest wart using an insulin syringe. Injections will be done at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
- Group C: 54 patients will be treated with both agents intralesionally into the largest wart using an insulin syringe at 2-week intervals until complete clearance will be achieved or for a maximum of five treatment sessions.
it is thought that candida antigen act through a cell-mediated immune response and bivalent HPV vaccine act mainly through humoral immunity, so we want to study their effect as single or mixed agents
Eligibility
Inclusion Criteria:
- patients with multiple, recalcitrant, or non-recalcitrant common warts of different sites, sizes, duration, and with or without distant lesions will be enrolled in the study
Exclusion Criteria:
- Pregnant female. Hypersensitivity to Candida antigen or bivalent HPV vaccine